• linkedin
  • Increase Font
  • Sharebar

    Adalimumab promising in treating JIA-associated uveitis, study finds

    Use of laser flare photometry can help clinicians assess treatment outcomes earlier

    Adalimumab can be an effective treatment in children with juvenile idiopathic arthritis (JIA)-associated uveitis.

    JIA-associated uveitis “is one of the most challenging inflammatory conditions in the pediatric population,” reported Bahram Bodaghi, MD, PhD, as there is little evidence-based data on therapeutic options, and glaucoma and cataract are the predominant complications (due to steroid treatment).

    “There is an inconstant efficacy of methotrexate,” said Dr. Bodaghi, professor of ophthalmology, University of Pierre and Marie Curie, Paris. “We had promising results with the adalimumab and the infliximab in a case series and in our open-label trials when the study was designed in 2009.”

    An earlier study found a relationship between laser flare values and complications of uveitis, with more than half of the patients reporting some complication during the follow-up period.

    “In a pediatric population, using the Standardization of Uveitis Nomenclature (SUN) criteria have not yet been validated,” Dr. Bodaghi said. This led to a multicenter, randomized, investigator-initiated, placebo-controlled phase III trial comparing adalimumab with placebo at 16 sites in France which enrolled 31 children.

     

    Adjuvite study details

    The primary endpoint was the efficacy of adalimumab versus placebo at 2 months, based on laser flare values.

    There was flare reduction of 30% (evaluated by laser flare photometry [LFP]) compared with baseline and no worsening of flare and cells at slit-lamp, Dr. Bodaghi said. Further, efficacy was shown through tapering from months 2 through 12.

    Researchers analyzed the transcriptomics on the blood of the enrolled children. Primary inclusion criteria included active uveitis associated with JIA, which could include polyarticular, LFP values > 30 photons perms for a normal below 7; resistance or intolerance to topical corticosteroids; resistance to systemic methotrexate used for at least 3 months; and possible evaluation of anterior chamber flare by LFP, and at least 4 years old weighing at least 15 kg (33 lbs).

    Primary exclusion factors included any previous treatment with anti-tumor necrosis factor (TNF), contraindication to systemic immunosuppressants or biologics, and some ocular contraindications-such as chronic blood-ocular barrier rupture, impossible monitoring of flare by laser flare, uncontrolled glaucoma, or any major ocular complications.
    The researchers considered responders those who showed a 30% reduction of flare values at month 2, with no worsening of inflammation based on the SUN criteria, Dr. Bodaghi said.

    The study itself had two phases. During the initial 2 months, the patients were randomized to either placebo (n = 15) or adalimumab (n = 16), then all patients received adalimumab 40 mg every 2 weeks for 1 year. The second phase was an open-label phase.

    Almost all the patients were female, (n = 15 in the adalimumab group, n = 13 in the placebo group), and both groups averaged about the same age (10 years), with each group having a duration of uveitis of about 4 years.

    “The mean laser flare values were about 99 in the adalimumab group and 70 in the placebo group,” Dr. Bodaghi said. “The disease was bilateral in 63% of the adalimumab group and 93% in placebo group.”

    There were 7 patients on oral steroids in the adalimumab group and 3 patients in the placebo group on oral steroids.
     

    Intent-to-treat analysis

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';